AgilePulse® Press Release
NEW Advanced Electroporation System for Vaccine Development
The New AgilePulse® In Vivo Electroporation System possesses unique, variable pulse amplitude technology for vaccine delivery or gene therapy applications.
Patented Pulse Agile® waveforms consist of multiple, low to high voltage pulses with variable pulse lengths, which promotes greater cell membrane poration; resulting in maximum transfection efficiency with minimal damage to the cells or tissues. Gene expression in skin is 100-fold higher1 when delivery is enhanced by electroporation compared to injection alone.
|•||Patented Pulse Agile® technology|
|•||Resistance measurement for proper needle placement and reproducibility|
|•||Specially designed needle arrays for intra-muscular or intra-dermal applications|
|•||Enhanced immune response1|
|•||Increased Ag-specific T-cell response1|
|•||Gene expression is 100-fold higher1|
To learn more about this exciting new technology or other BTX electroporation or electrofusion products, please contact us.
|1||Roos, A-K, et al., 2009 PLoS One 4(9)|